Supplementary Table 1 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts

Authors :: Rainer Kunstfeld
Christopher Gerner
Hubert Pehamberger
Christine Pirker
Andrea Bileck
Anastasia Meshcheryakova
Thomas Szekeres
Walter Jäger
Dagmar Födinger
Ruth Dingelmaier-Hovorka
Bernhard Knapp
Elisabeth Hofstätter
Philipp Paulitschke
Walter Berger
Verena Paulitschke
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Activity of vemurafenib and M8 against A375, M24met and V0, V0.1, V1, V10 (Proliferation assay).*Paulitschke et al. 2010

Full Text Access

Tools